Docoh
Loading...

ARMP Armata Pharmaceuticals

Filed: 26 Feb 20, 4:05pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 24, 2020

 

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

Washington001-3754491-1549568
(State or other jurisdiction of incorporation or
organization)
(Commission File Number)(IRS Employer Identification No.)

 

4503 Glencoe Avenue

Marina del Rey, California

 

90292

(Address of principal executive offices)(Zip Code)

 

(310) 655-2928

(Registrant’s Telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock ARMP NYSE American

 

 

 

 

  

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On February 24, 2020, the Board of Directors (the “Board”) of Armata Pharmaceuticals, Inc. (the “Company”) amended Section 2.8 of the Company’s Amended and Restated Bylaws, as amended (the “Amended Bylaws”). The purpose of the amendment was to reduce the minimum number of days required between the record date to determine stockholders of record of the Company’s outstanding common stock and the date on which the stockholder action or meeting would take place. Prior to the amendment, the record date was required to be not less than 30 days prior to the date of the stockholder action or meeting. The Board elected to reduce the minimum number of days after the record date to ten days, as permitted under the Washington Business Corporation Act. The full text of Section 2.8 of the Amended Bylaws (as amended) is set forth below, marked to show the changes that were adopted by the Board.

 

2.8 Fixing of Record Date for Determining Shareholders

 

For the purpose of determining shareholders entitled (a) to notice of or to vote at any meeting of shareholders or any adjournment thereof, (b) to demand a special meeting, or (c) to receive payment of any dividend, or in order to make a determination of shareholders for any other purpose, the Board may fix a future date as the record date for any such determination. Such record date shall be not more than seventy(70) days, and in case of a meeting of shareholders not less thanthirtyten (10) days prior to the date on which the particular action requiring such determination is to be taken. If no record date is fixed for the determination of shareholders entitled to notice of or to vote at a meeting, the record date shall be the day immediately preceding the date on which notice of the meeting is first given to shareholders. Such a determination shall apply to any adjournment of the meeting unless the Board fixes a new record date, which it shall do if the meeting is adjourned to a date more than one hundred twenty days after the date fixed for the original meeting. If no record date is set for the determination of shareholders entitled to receive payment of any stock dividend or distribution (other than one involving a purchase, redemption or other acquisition of the corporation's shares) the record date shall be the date the Board authorizes the stock dividend or distribution.

 

A copy of the amendment to the Amended Bylaws is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit
No.

 

Description

  
3.1 Amendment to Amended and Restated Bylaws of the Company (February 24, 2020).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 26, 2020Armata Pharmaceuticals, Inc.
  
 By:/s/ Steve R. Martin
 Name: Steve R. Martin
 Title:Chief Financial Officer